AI Summary
✦ ClarthaValuation Metrics
Trading 1.2% below historical median. Valuation is declining — currently in the undervalued zone (z-score: -0.15). Confidence: 76%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
12.33
Current
14.20
Overvalued
16.68
Undervalued
11.89
5Y Average
18.10
Current
20.84
Overvalued
21.89
Undervalued
12.82
5Y Average
1.41
Current
1.63
Overvalued
1.63
Undervalued
1.20
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.1x Undervalued | -58% vs avg | +43.2% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 161.4x Premium | +148% vs avg | -52.5% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 48.8x Undervalued | -25% vs avg | -17.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -33% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -33% vs avg | -25.8% |
UNICHEM LABORATORIES LTD trades at a discount (14.2x vs peer avg 65.0x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include ALIVUS LIFE SCIENCES LTD, COHANCE LIFESCIENCES LTD, CONCORD BIOTECH LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹315 CrDec 2025Latest net profit
₹-59 CrDec 2025Latest EPS
₹30.69Dec 2025Net margin
-9.1%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 347 | 334 | 362 | 399 | 390 | 437 | 448 | 461 | 384 | 357 | 315 |
| Expenses | 335 | 338 | 341 | 343 | 369 | 350 | 372 | 374 | 386 | 359 | 349 | 314 |
| Operating Profit | -52.84 | -19.05 | -34.57 | -6.3 | 5.37 | 14.09 | 38.11 | 45.76 | 47.51 | -4.19 | -22.41 | -28.63 |
| OPM % | -17.04% | -5.5% | -10.36% | -1.74% | 1.35% | 3.62% | 8.72% | 10.22% | 10.3% | -1.09% | -6.28% | -9.09% |
| Other Income | 3.79 | 5.83 | 7.58 | 74.73 | 7.04 | 8.77 | 7.08 | 18.93 | 6.05 | 4.25 | 21.4 | 15.03 |
| Interest | 2.93 | 2.48 | 3.82 | 2.36 | 1.76 | 1.38 | 1.82 | 2.89 | 1.53 | 1.93 | 3.68 | 2.1 |
| Depreciation | 28.32 | 27.36 | 27.26 | 25.62 | 25.22 | 26.11 | 26.39 | 28.45 | 27.47 | 29.93 | 30.11 | 30.02 |
| Profit before tax | -51.98 | -15.7 | -30.81 | 66.07 | 10.65 | 21.48 | 43.37 | 61.8 | 52.03 | -1.87 | -4.69 | -15.7 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 24.13% | 9.24% | 24.6% | -44.78% | -278.41% |
| Net Profit | -51.98 | -15.7 | -30.81 | 66.07 | 10.65 | 21.48 | 43.37 | 46.89 | 47.22 | -1.41 | -6.79 | -59.41 |
| EPS in Rs | -20.43 | -2.23 | -4.38 | 9.85 | -16.33 | 3.05 | 6.16 | 6.66 | 7.28 | -0.26 | -5.67 | 30.69 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.